A non-invasive tool to assess heart function and risk of heart failure.
A non-invasive, automated platform for hemodynamic assessment of patients at risk of heart failure or pulmonary hypertension
This study is working on a new, easy-to-use tool that can safely check how well your heart is working without any invasive procedures, making it especially helpful for people at risk of heart failure or pulmonary hypertension.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sensydia Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10953826 on NIH RePORTER |
What this research studies
This research focuses on developing a non-invasive, automated platform that accurately measures key hemodynamic parameters related to heart function, specifically targeting patients at risk for heart failure and pulmonary hypertension. The approach aims to simplify the diagnostic process by eliminating the need for invasive procedures like cardiac catheterization, which require specialized training and carry risks. By utilizing advanced algorithms and acoustic technology, the platform seeks to provide reliable measurements that can be performed easily and safely, allowing for earlier diagnosis and better monitoring of patients. This could lead to improved clinical decision-making and enhanced patient care.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are at risk for heart failure or pulmonary hypertension.
Not a fit: Patients with existing severe heart conditions requiring immediate invasive intervention may not benefit from this non-invasive approach.
Why it matters
Potential benefit: If successful, this research could provide a safer, more accessible method for diagnosing heart failure and pulmonary hypertension, ultimately improving patient outcomes.
How similar studies have performed: While non-invasive hemodynamic assessment is a novel approach, similar technologies have shown promise in improving patient monitoring and diagnosis in other cardiovascular conditions.
Where this research is happening
Los Angeles, United States
- Sensydia Corporation — Los Angeles, United States (Active)
Researchers
- Principal investigator: Mahajan, Aman — Sensydia Corporation
- Study coordinator: Mahajan, Aman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.